SNSilke V. Niederhaus

Silke V. Niederhaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Silke V. Niederhaus has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pancreas Transplantation for Recipients with Type 2 Diabetes Mellitus: Results of an International Survey

    by Jonathan A. Fridell, Pablo D. Uva, Aleksandra Kukla, Ava DeLonais-Parker, Rushda Faruk Mansuri, David Axelrod, Ty Dunn, Silke V. Niederhaus, Ronald Parsons, Henry Pleass, et al.

    Background.: Pancreas transplantation (PT), historically limited to patients with type 1 diabetes (T1D), is currently performed successfully in selected patients with type 2 diabetes (T2D). However, contemporary practice patterns and eligibility criteria for PT in T2D remain incompletely characterized. Methods.: The International Pancreas and Islet Transplant Association Pancreas Transplant Interest Group developed an electronic survey to assess center-level approaches to patient phenotyping, candidacy, and peri- and posttransplant management for PT in patients with T2D. The survey was distributed to international transplant professionals during an International Pancreas and Islet Transplant Association Pre-Congress meeting on June 15, 2025. Results.: Thirty-seven participants completed the survey. Most respondents’ programs offer PT for T2D only when a kidney transplant is also indicated. Fewer respondents’ programs also offer PT alone (10%), evaluate T2D candidates on a case-by-case basis (3%), or do not offer PT to patients with T2D (10%). Total daily insulin requirement and body mass index (BMI) were the most selected factors in determining eligibility. Considerable variability existed in metabolic thresholds: 62% of programs reported no C-peptide cutoff, whereas nearly half required a BMI of 2 for C-peptide-positive candidates. Respondents frequently recommend weight-optimization strategies, including lifestyle modification, glucagon-like peptide-1 receptor agonists, and bariatric surgery for candidates exceeding acceptable BMI thresholds. Surgical technique, induction, and maintenance immunosuppression and early posttransplant glycemic management were largely uniform between T2D and T1D recipients. Conclusions.: International practice reflects broad but heterogeneous adoption of PT for T2D, with most participants restricting its use to candidates requiring kidney transplantation and emphasizing integrated clinical phenotyping approaches.

  • Open Access

    Banff 2024 Pancreas Transplantation Report: Diagnosis and impact of chronic active T cell-mediated allograft rejection and re-evaluation of the indeterminate category with utilization of leukocyte immunostains in biopsies with ambiguous findings

    by Maike Büttner-Herold, Surya V. Seshan, Ivan Archilla, Alexei Mikhailov, John C. Papadimitriou, Krzysztof Grzyb, Karine Renaudin, Hector Mesa-Corrales, Saryn Doucette, Daniel J. Zaccarini, et al.


  • Open Access

    Evaluating Hyperparathyroidism in Simultaneous Pancreas‐Kidney Transplant Recipients: A Single‐Center Experience

    by Lane T. Cavey, Lindsay A. Kohan, Ruchin Patel, Mohamed M. Ibrahim, Hilary B. Whitlatch, Erin Foster, Raphael P. H. Meier, Silke V. Niederhaus

    Introduction: Cardiovascular disease remains the primary cause of mortality after kidney transplantation. Hyperparathyroidism (HPT) may contribute to the accelerated progression of coronary artery disease (CAD) and peripheral artery disease (PAD), particularly in transplant patients. This is particularly true when HPT overlaps with both renal failure and diabetes. Scant data exist to support medical or surgical management of tertiary hyperparathyroidism (3HPT) in simultaneous pancreas‐kidney (SPK) transplant recipients. This study evaluates the outcomes of cardiovascular disease, bone health, and kidney and pancreas graft function as they relate to HPT in SPK recipients.Methods: Patients who received SPK transplantation at a large academic center were reviewed. Patient demographics, transplant specifics, evidence of HPT, graft survival, and mortality were collected. Patients were categorized as either resolved HPT or unresolved HPT (developed 3HPT). Independent group t‐tests and Fisher's exact tests were used for bivariate comparisons.Results: Over 7 years, 132 patients received SPK transplantation. 41.7% of patients resolved HPT, and 58.3% of patients developed 3HPT. Those with 3HPT had significantly lower eGFR at 3 years (51.16 ± 21.58 vs. 62.55 ± 19.56 mL/min/1.73m2, p = 0.009) and higher HbA1c (6.05 ± 1.56 vs. 5.61 ± 0.83, p = 0.047). All patients experienced worsening radiographic evidence of large vessel calcifications (p < 0.001).Conclusions: 3HPT after SPK transplant is associated with worse function of both the renal and pancreatic grafts and peripheral arterial disease compared to those without 3HPT. A larger prospective cohort study is needed to determine causal relationships and develop treatment guidelines.


  • Long‐term outcomes after COVID‐19 infection in transplant recipients

    by Kaitlyn L. Freels, Kapil K. Saharia, John W. Baddley, Nadiesda A. Costa, Silke V. Niederhaus

    Background: Long‐term outcomes after COVID‐19 infection unique to solid organ transplant recipients (SOTR) are not published. We describe outcomes including readmission, allograft rejection, allograft dysfunction, allograft failure, and death.Methods: We conducted a retrospective cohort study of mostly unvaccinated SOTR with COVID‐19 from March 2020 to November 2021. Disease severity was assigned by NIH criteria. Data included demographics, clinical features, treatment, and outcomes and are presented as mean ± standard deviation or median (range).Results: One hundred and thirty‐eight SOTR were diagnosed with COVID‐19 at a median of 5 (IQR 3–8) years post‐transplant with a mean age of 57 ± 12 years at diagnosis. Forty‐one recovered at home; 97 were admitted. 12/32 (37.5%) SOTR with critical disease expired during initial admission. Among those who recovered, 48/126 (38.0%) had asymptomatic or mild infection, 31/126 (24.6%) had moderate, 27/126 (21.4%) severe, and 20/126 (15.9%) critical infection. 38/85 (44.7%) of SOTR who survived initial admission had 74 readmissions within 180 days (Figure 1). The 6‐month mortality rate among those who survived infection was 4/126 (3.2%). The mean time from initial infection to death was 32 ± 66 days in inpatient deaths and 95 ± 39 days in those who were discharged or never admitted. Six‐month graft dysfunction occurred in 18/125 (14.4%) and graft failure in 9/126 (7.2%); five failures were deaths with function.Conclusion: Readmissions after COVID‐19 infection were frequent after the index admission. Rejection was relatively infrequent; graft dysfunction at 6 months post‐infection was more common than rejection. Six‐month mortality following COVID‐19 recovery in SOTR was significant; close follow‐up of patients is warranted.

  • Medical Complications

    by Silke V. Niederhaus

  • Open Access

    Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting

    by Piotr Witkowski, Jon Odorico, Jordan Pyda, Roi Anteby, Robert J. Stratta, Beth A. Schrope, Mark A. Hardy, John Buse, Joseph R. Leventhal, Wanxing Cui, et al.

    The Food and Drug Administration (FDA) has been regulating human islets for allotransplantation as a biologic drug in the US. Consequently, the requirement of a biological license application (BLA) approval before clinical use of islet transplantation as a standard of care procedure has stalled the development of the field for the last 20 years. Herein, we provide our commentary to the multiple FDA’s position papers and guidance for industry arguing that BLA requirement has been inappropriately applied to allogeneic islets, which was delivered to the FDA Cellular, Tissue and Gene Therapies Advisory Committee on 15 April 2021. We provided evidence that BLA requirement and drug related regulations are inadequate in reassuring islet product quality and potency as well as patient safety and clinical outcomes. As leaders in the field of transplantation and endocrinology under the “Islets for US Collaborative” designation, we examined the current regulatory status of islet transplantation in the US and identified several anticipated negative consequences of the BLA approval. In our commentary we also offer an alternative pathway for islet transplantation under the regulatory framework for organ transplantation, which would address deficiencies of in current system.


  • Open Access

    The demise of islet allotransplantation in the United States: A call for an urgent regulatory update

    by Piotr Witkowski, Louis H. Philipson, Dixon B. Kaufman, Lloyd E. Ratner, Marwan S. Abouljoud, Melena D. Bellin, John B. Buse, Fouad Kandeel, Peter G. Stock, David C. Mulligan, et al.


  • Cannabis Dependence or Abuse in Kidney Transplantation: One Perspective

    by Silke V. Niederhaus

    Cannabis Dependence or Abuse in Kidney Transplantation: One Perspective Silke Niederhaus; Transplantation


  • Open Access

    Panniculectomy at the time of living donor renal transplantation: An 8-year experience

    by Ledibabari M. Ngaage, Adekunle Elegbede, Kashyap K. Tadisina, Selim G. Gebran, Brian M. Masters, Erin M. Rada, Arthur J. Nam, Joseph R. Scalea, Silke V. Niederhaus, Devinder Singh, et al.